Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Reach α-synuclein-dependent neurodegeneration: clinical development of therapeutic AFFITOPE vaccines for Parkinson’s disease and multisystem atrophy (SYMPATH)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Austria,France,France,Austria,Germany,France
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-10-01
End date: 2017-09-30
Duration (months): 48.0
Total project cost (EUR): 7699473.6
EU funding (EUR): 5999706.0
Participants: 8
Project status: CLOSED

The goal of SYMPATH is to advance clinical development of therapeutic vaccines targeting α-synuclein (aSyn)-driven neurodegenerative diseases (ND). It addresses Parkinson’s disease (PD) and multiple system atrophy (MSA), two synucleopathies, for which no causal therapy exists. Ultimately, both lead to patient disability and death, which along with patient number (PD) and age of onset (MSA, PD) define their high medical need status. The proposed programme focuses on 2 vaccine candidates, PD01A and PD03A, delivered by the innovative AFFITOME® technology. Both are peptide-protein conjugate vaccines and first-in-class candidates. They were selected to elicit antibodies neutralizing aSyn but sparing compensatory β-synuclein. Pre-clinical evaluation confirmed their disease-modifying activity in various models. The unprecedented clinical approach, called TANDEM strategy, uses the synergy resulting from applying 2 vaccine candidates in 2 complementary indications linked through their pathology. TANDEM PD/MSA capitalizes on (i) excellent clinical research centres and their associated national/European networks, (ii) platform methods assessing aSyn species as candidate biomarkers and (iii) preliminary clinical experience with PD01A, the first aSyn targeting vaccine ever tested in humans. Its core is formed by 2 phase I studies testing PD01A in MSA and PD03A in PD/MSA. Importantly, trial design (duration, endpoints, vaccine dose and schedule) will ensure collection of initial biomarker data connecting clinical results of PD- and MSA trajectories. SYMPATH defines the logical next development step of both AFFITOPE® vaccine candidates for synucleopathies and generates information/material (biobank) rendering them more amenable to rational drug development. Successful completion of the programme promises reaching aSyn pathology with an active vaccine as a causal therapy for PD/MSA, thus advancing one or both candidates as prime targets for product development and investment.

Keywords: parkinson's disease,multiple system atrophy,neurodegenerative diseases,active vaccination,clinical trial,therapeutic vaccines,healthy ageing
Image-guided pancreatic cancer therapy (IPACT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Netherlands,France,Germany,Netherlands,Finland,Germany
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2014-01-01
End date: 2018-10-31
Duration (months): 58.0
Total project cost (EUR): 8612064.03
EU funding (EUR): 5991070.0
Participants: 10
Project status: CLOSED

The aim of the iPaCT project is to address the unmet clinical need for an improved therapy of pancreatic cancer by developing a new integrated technology platform for image-guided thermal therapy. Yearly, 280000 new cases of pancreatic cancer are diagnosed worldwide. Being usually diagnosed late stage and without any efficient therapy available, basically all patients die with an average life expectancy of only a few months after diagnosis, leading to an overall low prevalence in society. Therefore, pancreatic cancer is a rare disease with an urgent clinical need for a new and improved therapeutic option. A potential breakthrough solution for the treatment of pancreatic cancer can be found in thermal therapies using high intensity focused ultrasound (HIFU) combined with local, temperature-triggered drug delivery. We propose a novel US-MR-HIFU system that integrates HIFU with two imaging modalities, i.e. Magnetic Resonance Imaging (MRI) and diagnostic Ultrasound (US) for image guidance of thermal ablation (T=60⁰C) and/or hyperthermia (T=42-43⁰C) of pancreatic tumours. For image-guided drug delivery, new temperature-sensitive nanocarriers will be developed that provide a high local dose of chemotherapeutic drug. Multimodal (molecular) imaging information, simultaneously acquired using the US-MR-HIFU platform, provides motion compensated temperature feedback as well as visualization of perfusion and drug uptake in the target tissue allowing personalized therapy. The consortium, including two innovative SMEs (Imasonic, Neagen), two hospitals (Klinikum der Universität München and University Medical Center Utrecht), Eindhoven University of Technology and Philips (a medical device company), represents the total chain from technology development, preclinical testing to clinical translation guaranteeing a clear route for later clinical use and a route to market for the SMEs partners, leveraging the competencies and strengths of a leading global healthcare company.

Keywords: pancreatic cancer therapy,high intensity focused ultrasound,magnetic resonance imaging,us-mr-hifu,image-guided drug delivery,temperature-sensitive liposomes,molecular imaging,personalized therapy
Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified. (CFMATTERS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Ireland,United Kingdom,France,United Kingdom,United States,Germany,Ireland,France,Germany,United Kingdom,Belgium
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-10-01
End date: 2017-06-30
Duration (months): 45.0
Total project cost (EUR): 7921629.53
EU funding (EUR): 5999748.0
Participants: 15
Project status: CLOSED

Antimicrobial resistance is arguably the most significant challenge facing the EU health care system. The unnecessary use of antibiotics is a key driver in the development of antibiotic resistance. Cystic Fibrosis (CF) represents a unique disease model to study bacterial resistance and to explore therapeutic strategies for same, as chronic lung infection overlaps with acute lung exacerbations caused by a multitude of organisms that traditionally evolve various mechanisms of resistance. With time, chronic polymicrobial infection develops, with the most dominant infecting organism being Pseudomonas aeruginosa, which is also important in other infections including wounds, burns and patients with medical devices, making it an important clinical target for the EU. In CF infections, empiric intravenous antibiotics are usually given for two weeks. Recurrent infections and treatments result in increasing antimicrobial resistance, and alterations in pathogen host interactions in the lung and gut flora. Next-generation DNA sequencing technology now offers DNA-based personalised diagnostics and treatment strategies. Enhancing our knowledge of the microbiome allows the use of stratified targeted antibacterial therapy that can be compared with standard empirical antibacterial therapy currently used. We believe this will reduce antibiotic usage, optimize dosage and duration startegies as the therapy will be tailored to the actual individual patient needs. Cystic Fibrosis Microbiome-determined Antimicrobial Therapy Trial in Exacerbations: Results Stratified (CF MATTERS) will provide a randomized multi-centre controlled trial of microbiome-derived antimicrobial treatments versus current empirical therapy. Simultaneously parallel human host-pathogen interaction studies in sputa, human gut microflora analysis and evaluation of murine exacerbation models will be performed. This will improve prescription practice and decrease antimicrobial usage and resistance.

Keywords: cystic fibrosis,microbiome,stratified antibacterial therapy,resistance,pathogen host interaction
Exploring the biological and socio-economic potential of new/emerging candidate fish species for the expansion of the European aquaculture industry (DIVERSIFY)

Framework: FP7 — Cooperation
Programme: Food, Agriculture and Fisheries, and Biotechnology
Destination: Sustainable production and management of biological resources from land, forest, and aquatic environment
Action type: Collaborative project
Countries involved: Greece,Spain,Spain,Israel,United Kingdom,Netherlands,Norway,Spain,France,Netherlands,Denmark,Italy,France,Spain,Belgium,Spain,Denmark,France,Germany,Spain,Belgium,Spain,Greece,Spain,Hungary
Call:  (FP7-KBBE-2013-7-single-stage, 2013)
Start date: 2013-12-01
End date: 2018-11-30
Duration (months): 60.0
Total project cost (EUR): 11782553.4
EU funding (EUR): 8961005.0
Participants: 41
Project status: CLOSED

The European aquaculture is a modern industry employing 190,000 people, with a €7 billion ex-farm value. This sector is well situated to be among world leaders in the efficient and sustainable production of safe seafood of the highest quality and nutritional value, taking into account consumer preferences and the large diversity of aquatic products from the wild. DIVERSIFY identified a number of new/emerging finfish species, with a great potential for the expansion of the EU aquaculture industry. The emphasis is on Mediterranean or warm-water cage culture, but also addressed are cold-water, pond/extensive and fresh water aquaculture. These new/emerging species are fast growing and/or large finfishes, marketed at a large size and can be processed into a range of products to provide the consumer with both a greater diversity of fish species and new value-added products. DIVERSIFY focuses on meagre (Argyrosomus regius) and greater amberjack (Seriola dumerili) for warm-water marine cage culture, wreckfish (Polyprion americanus) for warm- and cool-water marine cage culture, Atlantic halibut (Hippoglossus hippoglossus) for marine cold-water culture, grey mullet (Mugil cephalus) a euryhaline herbivore for pond/extensive culture, and pikeperch (Sanders lucioperca) for freshwater intensive culture using RAS. These species were selected based both on their biological and economical potential, and to cover the entire European geographic area and stimulate different aquaculture types. In collaboration with a number of SMEs, DIVERSIFY will build on recent/current national initiatives for species diversification in aquaculture, in order to overcome the documented bottlenecks in the production of these species. The combination of biological, technological and socioeconomic research planned in DIVERSIFY are expected to support the diversification of the aquaculture industry and help in expanding production, increasing aquaculture products and development of new markets.

Keywords: aquaculture,diversification,greater amberjack,meagre,pikeperch,atlantic halibut,wreckfish,grey mullet,sea cages,pond aquaculture,ras aquaculture,freshwater aquaculture,socioeconomics
The NGF system and its interplay with endocannabinoid signalling, from peripheral sensory terminals to the brain: new targets for the development of next generation drugs for neuropathic pain (PAINCAGE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Italy,Denmark,Austria,United Kingdom,Spain,France
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2014-04-01
End date: 2017-12-31
Duration (months): 45.0
Total project cost (EUR): 7878342.13
EU funding (EUR): 5860831.0
Participants: 9
Project status: CLOSED

So far, there are no effective treatments for neuropathic pain (NP), and current treatments suffer from serious unwanted side effects. The NGF ligand-receptor system has recently emerged as a novel target for NP of great therapeutic potential, a master regulator, controlling both neuropathic and inflammatory components. Besides being a multi-component system, it also modulates the endocannabinoid (EC) signalling. Blocking the NGF signaling system is therefore a rational and thoroughly validated approach to pain therapy. Extensive evidence for potent analgesic efficacy of antiNGF mAbs has been obtained in preclinical models and in clinical trials,showing remarkable analgesic efficacy and creating great expectations for this new class of analgesic compounds.However, potential safety concerns related to off-target side effects have been raised and recently the FDA called for more preclinical research. To fully exploit the huge therapeutic potential of NGF system, we built a consortium of leading researchers in the NGF, EC and pain scientific arena.The innovative proposal will investigate new strategies for the treatment of different NP forms, based on the NGF system and its interplay with EC signalling, focussing at different levels of the pain transmission and perception systems. The project results will provide solid, mechanism-based grounds for the development of already identified second-generation therapeutics, based on the “NGF target” system, as well as for the identification and validation of new druggable targets emerging from the elucidated mechanisms. It will also identify biomarkers for NP, validated in animal models and clinical samples, that could result in future clinical benefits, for the stratification of patients suffering from different neuropathies and their treatment. The project will contribute to the understanding and controlling NP mechanisms, with an interdisciplinary approach, leading to the development of next-generation NGF targeting drugs.

Keywords: nerve growth factor (ngf),monoclonal antibodies,neuropathic pain,p75ntr,trka,osteoarthritis,endocannabinoids,trpv1,epigenetics,cannabinoid,diabetes,hsan iv,hsan v,painless,human samples
Translating neuroimaging findings from research into clinical practice (PSYSCAN)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,Netherlands,Spain,United Kingdom,Netherlands,United Kingdom,Australia,Spain,Denmark,Germany,Ireland,Switzerland
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2014-02-01
End date: 2020-01-31
Duration (months): 72.0
Total project cost (EUR): 8336818.54
EU funding (EUR): 5998346.0
Participants: 22
Project status: CLOSED

Abstract 9 Neuroimaging (NI) has enormous potential to improve the clinical care of patients with psychiatric disorders, but has yet to deliver. The PSYSCAN project will address this issue directly by developing a NI-based tool that will help clinicians resolve key clinical issues in the management of patients with psychotic disorders. Clinicians will use the tool to assess patients with a standardised set of NI and complementary demographic, clinical, cognitive, and genetic measures. The clinician will enter data on to an iPad, and these data, along with NI data will be electronically transferred to a central facility for analysis. Key features of the analysis include the assessment of NI data at a network level, the integration of NI and non-NI data, and the use of machine learning methods to make predictions specific to the patient being assessed. The results will be delivered to the clinician’s iPad and will indicate the likelihood of a given clinical or functional outcome. The tool will have 3 clinical applications. PSYSCAN-Predict will facilitate prediction of the onset of psychosis in high risk subjects. PSYSCAN-Stratify will aid early diagnosis and the stratification of patients with first episode psychosis according to future course and outcome. PSYSCAN-Monitor will allow clinicians to measure progression of the disorder over time. The tool will be developed and validated in 2 large scale naturalistic studies using the consortium’s extensive network of centres. The validated tool will then be disseminated to clinical centres across the EU. The PSYSCAN project involves a world-class consortium of experts on NI and psychiatry that unites academic centres, SME’s with image processing and computerised testing expertise, a large medical device provider, and the pharmaceutical industry. The consortium is thus ideally suited to translating expertise and knowledge in NI to build a tool that can be used to improve the care of patients with psychiatric disorders.

Keywords: neuroimaging,psychiatry,stratification,prediction,biomarkers,machine learning
A research agenda on implementation research in chronic care. (IMPLEMENT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: Sweden,Netherlands,Netherlands
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-09-01
End date: 2015-08-31
Duration (months): 24.0
Total project cost (EUR): 549835.78
EU funding (EUR): 500000.0
Participants: 4
Project status: CLOSED

Europe’s population is growing older at a rapid pace, increasing the cost and threatening the future access and quality of healthcare in Europe. For a large part this is due to the rise of patients in need of chronic care. Healthcare in general, and chronic care in particular are in need of new ways of providing care, simply because the demand for chronic care cannot be met by the existing care infrastructure. At the same time Europe puts a lot of effort in funding research projects aimed at helping to build up innovative and sustainable healthcare systems in Europe. A surprisingly small number of outcomes of these projects are incorporated into actual care practice. This “implementation gap” keeps European citizens from benefitting from money spent on health research. This CSA therefore aims at taking implementation research (for chronic care) to the next level in order to enhance the scientific output and reap the benefits of its outcomes in everyday healthcare practice. This is done by combining knowledge from the organization of chronic care (Chronic Care Model) and knowledge from the young scientific field of implementation research. The main objective of this CSA will be to develop a Research Agenda for healthcare innovation implementation, focused on chronic care self-management support and delivery design. This will be done by performing an Assessment, involving 300+ experts on the knowledge and knowledge gaps concerning this topic. Next to the Assessment, a network (EU level and national) of institutions will be created, including science, industry, government, health care organizations, patients and professionals. This network will validate and later adopt the Research Agenda. The impact of this CSA is far fetching as it has the potential to influence the health of European citizens, the efficiency of the chronic care sector, the competitiveness of European medical devices industry and the effectiveness of the European funding of healthcare research.

Keywords: chronic,healthcare,innovation,implementation,strategy
High thermal insulating window frames for energy efficient buildings (THINFRAME)

Framework: FP7 — Capacities
Programme: Research for the benefit of SMEs
Destination: Research for SMEs
Action type: Research for the benefit of specific groups
Countries involved: Spain,United Kingdom,Germany,Spain,Italy,Italy
Call:  (FP7-SME-2013, 2013)
Start date: 2013-10-01
End date: 2015-09-30
Duration (months): 24.0
Total project cost (EUR): 1168000.68
EU funding (EUR): 883000.0
Participants: 6
Project status: CLOSED

The heat loss per area through windows (U-value) is still much greater (around 1.0 W/m2K) than through the building’s walls and roofs. Reduction of window heat loss is essential to reduce the energy use of buildings and their environmental impact as required by the recast Energy Performance of Buildings Directive (EPBD), Directive 2010/31/EU. While substantial effort has been made to improve glazing’s performance, frame’s properties need improvement as 30% of heat loss takes places through the frame. U-values below 0.7 W/m2K are required for best energy efficiency in nowadays buildings. Poly vinyl chloride (PVC) frames represent the highest market share (56%) in Europe due to better weather resistance than wood and lower maintenance required and over aluminium due to better insulating properties. Our solution includes the development of an insulating foam material made of polystyrene (PS) and polyethylene (PE) filled with a Phase Change Material (PCM). It will be processed in-line with the PVC profiles made by extrusion and will provide ease of adaptation to current production methods of the industries involved, lower heat loss of the windows installed (U-value of the frame lower than 0.7 W/m2K ), improved energy efficiency of buildings (savings of energy and CO2 emissions at European level) and cost-effective solution (below 200 €/unit) able to compete with PVC systems (as low as 170 €/unit) of lower insulation properties. THINFRAME’s SME proposers will achieve a leading position compared to their competitors due to the direct profits derived from their project participation since the market will continue to grow in the next years driven by the renovation works, the EU legislation on thermal efficiency as well as a continued annual net growth of the housing stock with around 0.5 million new buildings annually. Based on current market data and the expected market growth we can forecast profits of around 17 M€ in 5 years of commercial exploitation.

Keywords: poly (vinyl chloride),phase change material,polystyrene,polymer foaming,cell size,microencapsulation
PYROlysis based process to convert small WWTP sewage sludge into useful bioCHAR (PYROCHAR)

Framework: FP7 — Capacities
Programme: Research for the benefit of SMEs
Destination: Research for SMEs
Action type: Research for the benefit of specific groups
Countries involved: France,United Kingdom,Spain,Hungary,Italy,Türkiye,Switzerland
Call:  (FP7-SME-2013, 2013)
Start date: 2013-11-01
End date: 2015-10-31
Duration (months): 24.0
Total project cost (EUR): 1499697.4
EU funding (EUR): 1140000.0
Participants: 8
Project status: CLOSED

The PYROCHAR project brings together five SMEs and three research institutions to address the increasingly pressing issue of sewage sludge disposal in Europe. PYROCHAR will provide small municipalities and their waste water treatment plants (WWTPs) with an economically and environmentally sound solution for the treatment and disposal of their sewage sludge. The implementation of European Directives for waste water treatment, while improving general quality and management of wastewater in the Union, has led to a situation in which, today, 10 million tonnes of sewage sludge are produced annually across the 26 member states. More than 60% of the WWTPs in Europe service small municipalities. For these plants, the established sludge treatment and disposal options, developed specifically for large treatment plants, are too complex and expensive to provide on-site practical solutions. Because of this, small WWTPs face a number of challenges presented by sewage sludge: • They must comply with EU directives for wastewater treatment and sludge management. • The costs of sludge treatment, storage and transport to composting/incineration facilities, farming or to larger WWTPs for further treatment are high. • New technological solutions and those in development are focused on medium to large scale WWTPs. The adaptation of these to small scale plants requires investment and investigation that are simply not prioritised. • There is a high level of public mistrust of sewage sludge and its reuse, which widespread fears about adverse effects on the environment and human health. The PYROCHAR technology will thermochemically treat sewage sludge, converting it to biochar (biomass-derived charcoal) and synthesis gas (syngas) in a system with low operation and maintenance costs and compliant with EU regulations. The PYROCHAR technology’s re-use of energy and resources will offer the perfect solution for small municipalities in the €2 billion European marketplace of sewage sludge management.

Keywords: sewage sludge,pyrolysis,syngas,biochar,catalyst,syngas reforming,syngas cleaning,electricity generation,chp